Eiger BioPharmaceuticals Inc (CE) (EIGRQ) Noticias

EIGRQ: BK PLAN effective. All shares cancelled.

https://otce.finra.org/otce/dailyList?viewType=Deletions

EIGR changed to EIGRQ, bankruptcy. Delisted from the Nasdaq to the OTC: ***PPS at $1.72 in after hours.

https://otce.finra.org/otce/dailyList?viewType=Additions

down 10% today, expecting lower

down 4% today

expecting lower

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Uh oh

INDEFATIGABLE DUMPING

EIGR............................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783

EIGR.......................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783

EIGR new 52 week low

Hmmm

HORRENDOUS DUMPING

$50,000,000 share offering. This is adding approximately 1/6 the structure. Decent dilution still not enough to keep the doors open for a year.

lol

Nice analysis

lmao

monster rare drug play

very nice push coming....rare disease drugs are expensive!!

Literally losing over $440,000,000 million a year with only 3.4 mil revenue... Covid is a semi thing of the past now. This has potential to do a reverse split again imho in a year or 2. Not bashing but financials can't add up like this. Hi I'm spending half a Billion dollars a year and have basically zero revenue. Where's this going to come from to keep it going?

Volume is not sustainable imo and did a 15 to 1 Reverse split. They don't even have enough cash to cover 1 quarter. Was $0.86

watch and learn loser

Mid tripple digit negative profitability over 600% NEGATIVE. I don't think I have ever seen such big negative numbers on any ticker my entire life. While burning over $110,000,000 million a quarter... with revenues of 3 mil..

Profitability
Profit Margin -279.34%
Operating Margin (ttm) -633.66%

Management Effectiveness
Return on Assets (ttm) -35.62%
Return on Equity (ttm) -40.51%

Income Statement
Revenue (ttm) 12.14M
Revenue Per Share (ttm) 0.36
EBITDA -76.66M
Net Income Avi to Common (ttm) -33.92M
Diluted EPS (ttm) -1.00


Cash Flow Statement
Operating Cash Flow (ttm) -71.34M
Levered Free Cash Flow (ttm) -41.5M

EIGR monster

massive bio play taking off in pre!

jhpratt@alphavestcapital.com is my email.Please email me insights into eigr.


alphavestcapital.com

MOST IMPORTANT SUMMARY SENTENCES IN THE LANCET ARTICLE:(paraphrased: EIGR’s interferon works better than monoclonal antibodies at reducing covid viral load.Plus, EIGR’s interferon can be administered on an outpatient basis. )"Added value of this study This study shows that a single subcutaneous injection of 180 µg peginterferon lambda has an antiviral effect in outpatients with COVID-19. The decline in viral load was greater with peginterferon lambda treatment than with placebo. The more rapid viral load decline and higher clearance rate were most pronounced in those with high viral loads, a finding also reported with monoclonal antibody therapies in patients with COVID-19. However, the magnitude of the viral load decline compared with that of placebo was much greater with peginterferon lambda than has been reported with monoclonal antibody therapies to date. Peginterferon lambda was safe and well tolerated in outpatients with mild-to-moderate COVID-19, with a similar side-effect profile to that of placebo and no concerning laboratory adverse events. Implications of all the available evidence No approved therapy exists for outpatients with COVID-19. This study showed that peginterferon lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the assessment of antiviral agents for patients with COVID-19. Treatment early in the course of disease might prevent clinical deterioration and shorten the duration of viral shedding, which might have an important public health effect by reducing transmission and reducing the duration of self-isolation."

Dead though lol

more NEWS https://ih.advfn.com/stock-market/NASDAQ/eiger-biopharmaceuticals-EIGR/stock-news/83743438/eiger-biopharmaceuticals-sells-priority-review-vou

Let’s go over $20...

They say the right things in the conference call it should go bananas. The drug does have covid implications https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19

You think this rocks tomorrow penny chatter?

Think someone will be stated it. I looked and couldn't find it

Who’s the buyer?
I couldn’t find it...

Folks miss the covid implications here and they already have a buyer here https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19

It will sink it the magnitude of this drug, extending the life of these
children 2-1/2 years ....

I agree as it has 80% institutional ownership

Over $20 on Monday......

They didn't have to halt for this lol

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies

https://medlineplus.gov/genetics/condition/hutchinson-gilford-progeria-syndrome/

Progeria
Also known as: hutchinson-gilford progeria syndrome
OVERVIEW
SYMPTOMS
DIAGNOSIS
TREATMENT
A progressive genetic disorder where symptoms of aging are manifested at an early age.
How common is condition?
Extremely rare (Fewer than 1,000 cases per year in US)
Is condition treatable?
Treatments can help manage condition, no known cure
Does diagnosis require lab test or imaging?
Requires lab test or imaging
Condition Highlight
Present at birth, onset can be infantile or juvenile
Condition Highlight
May be dangerous or life threatening
Condition Highlight
Family history may increase likelihood

What kind of fda approval don't see interest?

On it

HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ
T1

EIGR - Lambda is most paradoxical interferon :
“ IFN-lambda responses to dsRNA in the human infant airway epithelium are regulated by p38-MAPK and NF-kB signaling. High in vivo IFN-lambda production is influenced by virus type and associated with recurrent respiratory sick visits in young children.”


https://scholar.google.com.hk/scholar?start=50&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DpIKe3q7igMIJ

A mutual friend we have really likes it.

Small share structure is compelling...

EIGR is expected to release interim data from its Stanford Lambda Trial - I’m not too excited, given the emergent need for any slightly positive data regarding the treatment of SARS2 -see Remdesivir 4 day advantage- and the failure of the data monitoring committee - who already had their interim look/- to halt the study on efficacy - a little bird told me (when I was a vocal advocate of EIGR on Twitter)- that the data was less than compelling to that point weeks ago - certainly that might have changed. The recent insider buy certainly makes on hopeful that it has. A recent seeking alpha pump suggests the upcoming Progeria approval carries tge rest of the pipeline - have you seen how rare Progeria is?

https://seekingalpha.com/instablog/52316800-friar-tuck-esq/5480909-eiger-biopharmaceuticals-low-risk-biotech-10-bagger-near-term-catalyst

$EIGR what is Cooking?

EIGR is cooking...

EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.”
https://www.frontiersin.org/articles/10.3389/fneur.2020.00146/full

On EIGR (Lambda is IFN III) “Treatment with type I and III IFNs can dramatically inhibit SARS-CoV-2 replication in primary human airway epithelial cells with the corresponding induction of ISGs.22 The role of type III IFNs in the suppression of virus replication has been highlighted.23,24 Type III IFN shows a better treatment option than type I IFN for influenza A virus-induced disease for its induction of antiviral immunity without the pro-inflammatory responses.”


https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1.full.pdf